The Medicare Drug Pipeline

Published February 2026 · Updated July 2026 · 18 min read

The Specialty Drug Revolution

Medicare drug spending is being driven by a handful of extraordinarily expensive specialty drugs. Aflibercept (Eylea), used for macular degeneration, is the single most expensive drug in Medicare — generating nearly $20 billion in payments over the decade. Cancer drugs, immunotherapies, and biologic agents make up the rest of the top tier.

The shift toward specialty drugs represents a fundamental transformation of Medicare spending. A decade ago, the most common Medicare drugs were generic statins, blood pressure medications, and diabetes pills. Today, the top drugs by spending are biologics and specialty injectables that cost thousands of dollars per dose.

This transformation reflects both scientific progress and economic reality. Biologics are extraordinarily effective — immunotherapies have turned some cancers from death sentences into manageable chronic conditions, and anti-VEGF agents have prevented millions of cases of blindness. But their prices are set in a market with limited competition, patent protections that last decades, and a payment system that provides little incentive for cost-consciousness.

The Eye Care Phenomenon

Ophthalmology drugs dominate Medicare Part B spending in a way that surprises most people. Aflibercept (Eylea), ranibizumab (Lucentis), and other anti-VEGF agents used for wet macular degeneration collectively account for over $30 billion in Medicare payments over our 10-year dataset.

These drugs are administered as intravitreal injections — literally injected into the eye — every 4-8 weeks. Each injection costs Medicare $1,800-$2,200. A single patient may receive 20-30 injections over the course of treatment. With millions of aging baby boomers developing age-related macular degeneration, this spending category is projected to continue growing.

The Oncology Pipeline

Cancer treatment is the second-largest driver of Medicare drug spending. Immunotherapy drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) have revolutionized cancer care — but at extraordinary cost. A year of Keytruda treatment can exceed $150,000, and these drugs are increasingly used in combination therapies and earlier-stage cancers, expanding the total spending.

Why It Matters

As drug costs grow faster than overall Medicare spending, they consume an ever-larger share of the program's budget. The Inflation Reduction Act's drug price negotiation provisions were designed to address this — but they only apply to a small number of drugs initially. The broader trend of specialty drug dominance shows no signs of slowing.

The IRA's Impact: Early Results

The Inflation Reduction Act's Medicare drug negotiation provisions took effect in 2026, with the first 10 negotiated prices now in place. Early data suggests savings of 20-60% on the targeted drugs — representing estimated savings of $6 billion in the first year alone. However, critics point out that these 10 drugs represent a fraction of total Medicare drug spending, and pharmaceutical companies have filed legal challenges that could limit the program's scope.

The second round of 15 drugs was selected in early 2026, with negotiated prices to take effect in 2027. Notable inclusions: several high-cost cancer immunotherapies and diabetes treatments.

The 340B Controversy

The 340B Drug Pricing Program allows certain hospitals and clinics to purchase drugs at deeply discounted prices (typically 25-50% off) while billing Medicare at the standard ASP+6% rate. This spread generates significant revenue for 340B-eligible entities — but critics argue the savings often aren't passed on to patients. The program has grown from $12 billion in discounted purchases in 2015 to over $44 billion in 2023, with ongoing debate about whether it achieves its original goal of supporting safety-net providers.

The ASP+6% Problem

Medicare Part B pays for physician-administered drugs at Average Sales Price (ASP) plus 6%. This payment methodology creates a perverse incentive: physicians who administer more expensive drugs earn a higher margin. A $10,000 drug generates $600 in physician revenue, while a biosimilar priced at $6,000 generates only $360. This "spread pricing" has been widely criticized by health economists as a barrier to biosimilar adoption and cost-effective prescribing.

The Weight-Loss Drug Question

GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) represent the next potential budget-buster for Medicare. While currently Medicare is prohibited from covering weight-loss drugs, the Treat and Reduce Obesity Act — reintroduced in 2025 — would change that. If passed, CMS estimates coverage could cost $35-50 billion annually, given that 42% of Medicare beneficiaries are obese.

Even without obesity coverage, Medicare already pays for these drugs when prescribed for diabetes (their FDA-approved indication). Semaglutide spending in Medicare Part D has grown 400% since 2020, making it one of the fastest-growing drug categories in the program.

Part B vs Part D: Where the Money Flows

Medicare drug spending splits across two programs: Part B covers drugs administered in physician offices and outpatient settings (injections, infusions, chemotherapy), while Part D covers self-administered drugs (pills, inhalers, insulin pens). The top 30 drugs below are Part B — physician-administered drugs that generate the highest per-unit payments.

Part B drug spending is more concentrated than Part D: fewer drugs, but each generating massive total payments. Part D spending is spread across thousands of drugs but is growing faster overall, driven by specialty pharmacy and the GLP-1 surge.

The White Bagging Controversy

"White bagging" is a growing practice where health plans require physicians to use specialty pharmacy-dispensed drugs rather than purchasing drugs through traditional buy-and-bill channels. This shifts the supply chain — and the associated margin — from physician practices to pharmacy benefit managers. Physicians argue white bagging creates safety concerns (drug handling, temperature control) and reduces their revenue, while payers say it reduces costs through better price negotiation.

Several states have passed anti-white-bagging legislation, and the debate has implications for Medicare Part B drug spending: if white bagging becomes standard, it could change how ASP is calculated and how physicians are compensated for drug administration.

Our Analysis

OpenMedicare tracks every Part B drug code in CMS's dataset — over 500 unique drug codes billed by hundreds of thousands of providers. Our drug spending analysis aggregates 10 years of data to show which drugs cost the most, which providers bill the most drug codes, and how drug spending has shifted over time.

Explore the full dataset on our drug spending dashboard, or search for any specific drug by HCPCS code to see which providers bill it most and how spending has trended over time.

Want to see how your doctor's drug prescribing compares to peers? Our provider search shows drug vs. non-drug billing breakdown for every Medicare provider.

The drug pipeline isn't just a policy issue — it's personal for the millions of Medicare beneficiaries who depend on these medications. Understanding where the money goes is the first step toward ensuring it goes where it should.

As new therapies enter the pipeline — from Alzheimer's treatments to cell therapies to next-generation cancer drugs — the pressure on Medicare's drug budget will only intensify. The choices made today about pricing, negotiation, and payment reform will determine whether Medicare can afford the cures of tomorrow.

The Drug Fraud Angle

High-cost drugs create fraud opportunities. Some providers have been caught billing for expensive drugs while administering cheaper alternatives (or nothing at all), diluting drug doses to stretch them further, or using "buy and bill" arbitrage — purchasing drugs at discounted rates while billing Medicare at ASP+6%. Our fraud watchlist tracks providers with suspicious drug billing patterns.

Top 30 Drugs by Medicare Spending